Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

GENOMIC VALLEY BIOTECH LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹43.63
at close · 28 Oct 2026
▲ 2.07 (+4.98%)

Latest filings

Next results: Fri, 30 Oct · Financial Results
  1. Open offer for up to 794,170 GVBL equity shares · Strategic Transactions
  2. Board meeting on Oct 30 to consider Q2 and H1 FY26 financial results · Results
  3. Promoters sell 46.06% stake; acquirers gain control and must make open offer · Strategic Transactions
All filings ↓
Ask Nexa about GENOMIC VALLEY BIOTECH LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹0 Cr over the trailing twelve months.

Market Cap
₹13 Cr
P / E (TTM)
363.6×
EV / EBITDA
395.3×
Div Yield
—
Growth
5.2%▲
Revenue 5y CAGR
PAT — · EBITDA —
Quality
1.1%·
ROCE (5y median)
ROE 0.8% (5y median) · margin 16.3%
Leverage
0.00·
Debt / Equity · low
Net debt ₹0 Cr
Revenue FY21→FY26
1.3×▲
Margin +280.0 pts
₹0 Cr → ₹0 Cr
Cash conversion
-3.06×▼
Operating cash ÷ profit · 5 yrs
₹-3 Cr on ₹1 Cr
Moves on a normal day
3.03%·
Median daily move
Last 251 sessions · the yardstick for filing-day moves
Where it sits among 191 Pharmaceuticals & Biotechnology peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#161/164
P/B#97/169
ROCE#152/189
ROE#141/172
Debt / Equity#1/172
EBITDA margin#10/170
Revenue growth#159/166
Profit growth#130/164

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals & Biotechnology peers · as of FY26 — not investment advice

Strengths
No borrowings on the balance sheet
lower than 78% of its 172 Pharmaceuticals & Biotechnology peers
Concerns
Returns on capital 1.1% (5-year median)
#152 of 189 in Pharmaceuticals & Biotechnology on the latest reported figures · up from −4.8% in FY21
Over 5 years it reported ₹1.04 Cr of profit and an operating cash outflow of ₹3.18 Cr — -3.06×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 3542 days of cash tied up
Customers are taking longer to pay — 114 → 3162 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from GENOMIC VALLEY BIOTECH LIMITED's filed financials and exchange disclosures

What does GENOMIC VALLEY BIOTECH LIMITED do?

GENOMIC VALLEY BIOTECH LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.

Is GENOMIC VALLEY BIOTECH LIMITED profitable?

Yes. Over the trailing twelve months GENOMIC VALLEY BIOTECH LIMITED reported a net profit of ₹0.02 Cr on revenue of ₹0.22 Cr.

Does GENOMIC VALLEY BIOTECH LIMITED pay a dividend?

Not in the latest reported year — GENOMIC VALLEY BIOTECH LIMITED's dividend payout for FY26 was nil.

Is GENOMIC VALLEY BIOTECH LIMITED debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.00 Cr of cash.

Is GENOMIC VALLEY BIOTECH LIMITED expensive compared with its peers?

On trailing P/E, GENOMIC VALLEY BIOTECH LIMITED ranks 161 of 164 in Pharmaceuticals & Biotechnology — cheaper than 2% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the GENOMIC VALLEY BIOTECH LIMITED share price move in a day?

On a typical session GENOMIC VALLEY BIOTECH LIMITED moves 3.03% — that is the median absolute close-to-close move across its last 251 trading days. MarketPing measures each filing's price reaction against it.

When are GENOMIC VALLEY BIOTECH LIMITED's next results?

Financial Results on Fri, 30 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track GENOMIC VALLEY BIOTECH LIMITED's announcements?

Every NSE and BSE filing by GENOMIC VALLEY BIOTECH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.